SILODOZIN. OT ISSLEDOVANIY K KLINIChESKOMU PRIMENENIYu: SELEKTIVNOST', BEZOPASNOST' I DLITEL'NAYa EFFEKTIVNOST'


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

References

  1. www.sciencedirect.com
  2. www.europeanurology.com
  3. Girman C. J., Jacobsen S. J., Rhodes T., Guess H. A., Roberts R. O., Lieber M. M. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35:277-84.
  4. Wei J. T., Calhoun E., Jacobsen S. J. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005;173:1256-61
  5. Parsons J. K., Bergstrom J., Silberstein J., Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology 2008;72:318-21.
  6. Andersson K. E., Gratzke C. Pharmacology of alphal-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 2007;4:368-78.
  7. Andersson K. E. Treatment-resistant detrusor overactivity underlying pharmacology and potential mechanisms. Int J Clin Pract Suppl 2006;151:8-16.
  8. Roosen A., Chapple C. R., Dmochowski R. R. et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic reviewof the latest literature. Eur Urol 2009;56:810-20.
  9. Nickel J. C., Sander S., Moon T.D. Ameta-analysis ofthevascularrelated safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int 3 Clin Pract 2008; 62;1547—59.
  10. Schilit S., Benzeroual K. E. Silodosin: a selective alphalA-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin Ther 2009;31;2489-502.
  11. Guimarães S., Moura D. Vascular adrenoceptors; an update. Pharmacol Rev 2001;53:319-56.
  12. Andersson K. E., Lepor H., Wyllie M. G. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate 1997;30:202-15.
  13. Shibata K., Foglar R., Horie K. et al. KMD-3213, a novel, potent, alpha la-adrenoceptor-selective antagonist; characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 1995;48:250-58.
  14. Martin D. J. Preclinical pharmacology of alpha l-adrenoceptor antagonists. Eur Urol 1999;36(Suppl 1):35-41.
  15. Lepor H., Hill L. A. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular olerability. Pharmacotherapy 2010;30:1303-12.
  16. Strittmatter F., Hedlund P. Silodosin — from preclinical development To clinical trials. Aging Health 2011;7:45-57.
  17. Murata S., Taniguchi T., Muramatsu I. Pharmacological analysis of the novel, selective alphal-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand. Br J Pharmacol 1999;127:19-26.
  18. Murata S., Taniguchi T., Takahashi M., Okada K., Akiyama K., Muramatsu I. Tissue selectivity of KMD-3213, an alpha(l)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol 2000;164;578—83.
  19. Yamagishi R., Akiyama K., Nakamura S. et al. Effect of KMD-3213, an alpha la-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur J Pharmacol 1996; 315: 73-9.
  20. Moriyama N., Akiyama K., Murata S. et al. KMD-3213, a novel alphalAadreuoceptor antagonist, potently inhibits the functional alphal-adrenoceptor in human prostate. Eur J Pharmacol 1997;331:39-42.
  21. Akiyama K., Hora M., Tatemichi S. et al. KMD-3213, a uroselective and long-acting alpha(la)-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 1999;291:81-91.
  22. Akiyama K., Noto H., Nishizawa O. et al. Effect of KMD-3213, an alphalA-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol 2001; 8:177-83.
  23. Tatemichi S., Tomiyama Y., Maruyama I. et al. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Neurourol Urodyn 2006;25:792-99.
  24. Kobayashi S., Tomiyama Y., Tatemichi S., Hoyano Y., Kobayashi M., Yamazaki Y. Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia. Eur J Pharmacol 2009;613;135-40.
  25. Gu B. J., Ishizuka O., Igawa Y., Nishizawa O., Anderson K. E. Role of supraspinal alphal-adrenoceptors for voifling in conscious rats with and without bladder outlet obstruction. J Urol 2002;167:1887-91.
  26. Yoshizumi M., Matsumoto-Miyai K., Yonezawa A., Kawatani M. Role of supraspinal and spinal alphal-adrenergic receptor subtypes in micturition reflex m conscious rats. Am 3 Physiol Renal Physiol 2010;299:F785-91.
  27. Yazaki J., Aikawa K., Shishido K. et al. Alphal-adrenoceptor antagonists improve bladder storage function through reduction of afferent activity m rats with bladder outlet obstruction, Neurourol Urodyn 2011;30;461-67.
  28. Yokoyama O., Ito H., Aoki Y., Oyama N., Miwa Y., Akino H. Selective alA-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity. World 1Urol 2010;28:609-14.
  29. Sun Y., MaLossi, Jacobs C., Chai T. C. Effect of doxazosin on stretchactivated adenosine triphosphate release in bladder mothelial cells from patients with benign prostatic hyperplasia. Urology 2002;60; 351-56.
  30. Yanase H., Wang X., Momota Y., Nimura T., Kawatani M. The involvement of urothelial alphalA adrenergic receptor in controlling the micturition reflex. Biomed Res 2008;29:239-44.
  31. Kurizaki Y., Ishizuka O., Imamura T. et al. Relation between expression of a(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Scand J Urol Nephrol 2011;45:15-9.
  32. Morganroth J., Lерor H., Hill L. A., Volinn W., Hoel G. Effects of theselective alpha la-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo-and moxifloxacincontrolled study. Clm Pharmacol Ther 2010; 87:609-13.
  33. Marks L. S., Gittelman M. C., Hill L. A. et al. Rapid efficacy of the highly selective alA-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of phase 3 studies. J Urol 2009;181:2634-40.
  34. Chapple C. R., Montorsi F., Tammela T. L. J. et al. on behalf of the Еurореаn Silodosin Study Group. Silodosin Study Group therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placeboand active-controlled clinical trial performed in Europe. Eur Urol 2011;59:342-52.
  35. Nickel J. C., O'Leary M. P., Lepor Н. et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase П multicenter, double-blind, placebo controlled study. J Urol 2011; 186:125-31.
  36. Kawabe К., Yoshida М., Нопппа Y. Silodosin Clinical Study Group. Silodosin, a neu alphalA-adrenoceptor-selective antagonist for treating benigu prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double blind study in Japanese men. BJU Int 2006;98:1019-24.
  37. Marks L. S., Gittelman M. C., Hill L. A., Volinn W., Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 2009; 74: 1318-22.
  38. European Medicines Agency. COMP Assessment report for Silodyx. Doc. Refs ЕМА!72316/2010.
  39. MacDiarmid S. A., Hill L. A., Volinn W., Ное G. Lack of pharmacodynamic interaction of silodosin, a highly selective alphalaadrenoceptor alphalaadrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology 2010;75:520-25.
  40. Michel M. C., Casi M., Antonellini А. Silodosin consistently improves nocturia in men with LUTS suggestive of ВРА, Analysis of three phase Ш placebo controlled studies. Eur Urol Suppl 2011;10; 121-22.
  41. Yu H.J., Lin A.T., Yang S.S. et al. Non-inferiority of silodosin to tamsulosin ш treating patrents with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int. In press. D0I:10.1111/j.1464-410X.2011.10233.
  42. Магадана Y., Gotoh М., Komatsu T., Funahashi Y. et al. Efficacy of silodosin for relieving berugn prostatic obstruction: prospective pressure Мои study. J Urol 2009;182:2831-35.
  43. Takao T., Tsujimura А., Kiuchi Н. et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int 1Urol 2008;15;992-96.
  44. Miyakita Н., Yokoyama E., Onodera Y. et al. Short term effects of crossover treatment with silodosin and tardsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol 2010;17:869-75.
  45. Yokoyama Т., Наrа R., Fukumoto К. et al. Effects of tluee types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int 1Urol 2011;18 225-30.
  46. Yamanishi T., Mizuno Т., Tatsumiya К., Watanabe M., Kamai T., Yoshida К. Urodynamic effects of silodosiu, a new alpha IAadrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn 2010;29:558-62.
  47. Lepor Н. Long term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998; 51;901-906.
  48. Roehrborn C. G., Kaplan Z. А., Lepor Н., Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis 2011;14:143-48.
  49. Shimizu F., Taguri М., Harada Y., Matsuyama Y., Sase К., Fujime M. Impact of dry ejaculation caused by highly selective alpha1Ablocker: randomized, double-blind, placebo-controlled crossover pilot study in healthy volunteer men. 7 Sex Med 2010;7:1277-83.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies